Quotes delayed at least 20 minutes.
Information provided by TurboFeed.

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA’s exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from Genentech for RAPTIVA® (efalizumab) and LUCENTIS® (ranibizumab injection). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.

Recent News

May 12, 2008
XOMA Refinances Royalty-Based Loan Facility for $55 Million

May 12, 2008
XOMA Reports First Quarter 2008 Financial Results

more »